Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last €14.40 EUR
Change Today +0.11 / 0.77%
Volume 0.0
A8D On Other Exchanges
EN Paris
As of 7:08 AM 07/3/15 All times are local (Market data is delayed by at least 15 minutes).

ab science sa (A8D) Snapshot

Previous Close
Day High
Day Low
52 Week High
02/10/15 - €17.86
52 Week Low
10/17/14 - €7.14
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for AB SCIENCE SA (A8D)

Related News

No related news articles were found.

ab science sa (A8D) Related Businessweek News

No Related Businessweek News Found

ab science sa (A8D) Details

AB Science S.A., a pharmaceutical company, engages in the discovery, development, and commercialization of protein kinase inhibitors for use in human and veterinary medicines. The company markets Masitinib for the treatment of oncology and inflammatory diseases for dogs and cats. It markets its Masitinib under the Masivet brand name in Europe; and Kinavet brand name in the United States. The company is also developing Masitinib in human indications that are in various Phase II and Phase III clinical trials for the treatment of oncology, inflammatory, hematology, and central nervous system diseases, as well as for the treatment of indolent systemic mastocytosis, non controlled severe asthma, refractory rheumatoid arthritis, progressive forms of multiple sclerosis, amyothrophic lateral sclerosis, and Alzheimer's diseases. It serves hospitals and specialist physicians. AB Science S.A. was founded in 2001 and is headquartered in Paris, France.

121 Employees
Last Reported Date: 04/30/15
Founded in 2001

ab science sa (A8D) Top Compensated Officers

Co-Founder, Chairman, Chief Executive Officer...
Total Annual Compensation: €456.7K
Compensation as of Fiscal Year 2013.

ab science sa (A8D) Key Developments

AB Science SA Provides Update on Phase 1/2 Program with masitinib in Solid Tumors

AB Science SA presented an update of its masitinib phase 1/2 program in solid tumors. AB Science has developed an extensive phase 1/2 program in solid tumors with masitinib to ascertain which indications should be pursued in phase 3. Each of these phase 2 study designs incorporated a pre-defined statistical test to detect a superiority trend in overall survival between masitinib in combination with standard-of-care chemotherapy when compared against its relevant historical meta-analysis benchmark. The outcome of this test determines whether or not a confirmatory phase III study should be initiated. This statistical test was considered positive based on the upper bound for the confidence interval of Hazard Ratio being lower than 1, which corresponds to a relative survival benefit for patients in the masitinib treatment-arm. Out of the phase 2 studies initiated: Four studies passed their predefined statistical test instigating launch of randomized controlled phase 3 studies in each indication. Those indications include the digestive cancers of GIST, gastric cancer and colorectal cancer, as well as prostate cancer. One study passed its predefined statistical test in triple negative breast cancer. A decision to move to phase 3 is pending results from an on-going phase 2 study in breast metastatic cancer. One study in T cell refractory lymphoma was accelerated to a phase 3 randomized controlled trial validated by health authorities in the world. Three studies did not meet their pre-specified statistical test and a decision has been made not to launch phase 3. Those studies were non small cell lung (NSCL) cancer, metastatic melanoma not bearing the juxtamenbrane mutation of c-Kit, and glioblastoma. Three studies are still on-going, in breast cancer, liver cancer, and head & neck cancer. From this phase 1/2 clinical program the following comments can be made: Masitinib seems to be particularly effective in digestive cancers where phase 2 data looks encouraging with respect to relevant benchmark data. Consequently, phase 3 studies are on-going or in the process of being launched in GIST, pancreatic cancer, colorectal cancer, and gastric cancer (esophagogastric adenocarcinoma). These results are compatible with the known mechanism of action for masitinib. Pre-clinical data and cumulative clinical experience show that masitinib may be capable of generating an important survival benefit in various cancers by targeting mast cells and macrophages. Masitinib acts as a modulator of the tumor microenvironment. The expected consequence of these actions is to extend survival by controlling the aggressiveness, transformation, and dissemination of the tumors. Publications have shown that there is a higher prevalence of both mast cellsA and tumor associated macrophagesB in digestive cancers when compared with other cancers. Furthermore, both cells have been identified as a negative prognosis factor on survival. Thus, masitinib may retard the aggressive course of tumor progression in certain patients with these digestive system cancers. A second group of cancers that appear susceptible to masitinib treatment are hormonal cancers such as prostate cancer and breast cancer. It is still however too early to say this with certainty, because results from the metastatic breast cancer study are still unknown. Abstracts reporting phase 1/2 results for colorectal cancer3, gastric cancer4, and triple negative breast cancer5 have been presented at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting.

AB Science S.A., Annual General Meeting, Jun 22, 2015

AB Science S.A., Annual General Meeting, Jun 22, 2015.

AB Science S.A. Presents at French Life Science Days conference, Jun-17-2015

AB Science S.A. Presents at French Life Science Days conference, Jun-17-2015 . Venue: W Hotel, 541 Lexington Avenue, New York, NY 10022, United States.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
A8D:GR €14.40 EUR +0.11

A8D Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for A8D.
View Industry Companies

Industry Analysis


Industry Average

Valuation A8D Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 197.4x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 182.9x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact AB SCIENCE SA, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at